Ultra-early detection of failed recovery after stroke using cerebral autoregulation during thrombectomy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective observational diagnostic accuracy study that records cerebral autoregulation (CA) measures during endovascular thrombectomy in adults with anterior-circulation large-vessel occlusion. Researchers will enroll 129 participants split into modeling and validation cohorts and follow clinical outcomes at 24 and 48 hours, 7 days (or discharge), and 90 days. The primary aim is to determine whether intraoperative CA impairment predicts futile recanalization—poor functional outcome despite achieving mTICI 2b-3 reperfusion. No experimental therapies are given; CA metrics will be linked to clinical outcomes to build and test predictive models.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18
2. Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA.
3. NIHSS score ≥ 6 obtained prior to endovascular treatment.
4. Modified Rankin Scale ≤ 1 prior to qualifying stroke.
5. Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time).with reaching the goal of mTICI grade 2b-3
6. For patients with symptom onset within 6 hours: ASPECTS ≥ 3; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3.
7. Patient/Legally Authorized Representative has signed the Informed Consent Form.

Exclusion Criteria:

1. Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes.
2. Baseline CT/MRI confirms the presence of arterial dissection.
3. Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.
4. Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics.
5. Severe infection (e.g. sepsis) or multiple organ failure.
6. Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; oral anticoagulant therapy with INR \> 3; or use of a factor Xa inhibitor within the preceding 48 hours with an abnormal aPTT.
7. Baseline platelet count \< 50 × 10\^9/L.
8. Blood glucose concentration\<50 mg/dL (2.7 mmol/L) or \>400 mg/dL (22.2 mmol/L).
9. Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\>185 mmHg or diastolic blood pressure\>110 mmHg).
10. Severe cardiomyopathy with heart failure (LVEF ≤ 30% or NYHA class IV), acute myocardial infarction, or unstable angina.
11. Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.
12. Current hemodialysis or peritoneal dialysis; known severe renal insufficiency with estimated glomerular filtration rate \< 30 mL/min or serum creatinine \> 220 μmol/L (2.5 mg/dL).
13. Known intracranial aneurysm, and cerebral arteriovenous malformation.
14. Malignant brain tumor or CNS infection.
15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)
16. Female who is pregnant or lactating at time of admission.
17. Anticipated life expectancy \< 6 months.
18. Current participation in another investigational drug or device study.
19. local skin damage or other conditions that cannot cooperate with electrode sticking.
20. severe agitation or other conditions affecting data collection.

Where it's running

• Beijing Shijitan Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• The First Affiliated Hospital of Harbin Medical University
  Harbin, Heilongjiang, China Recruiting
• Weifang People's Hospital Affiliated to Weifang Medical University
  Weifang, Shandong, China Recruiting
• Dalian Municipal Central Hospital
  Dalian, Liaoning, China Not yet recruiting

Study contacts

• Principal investigator: Shen Li — Beijing Shijitan Hospital, Capital Medical University
• Study coordinator: Zidong Li
• Email: walx592815088@163.com
• Phone: 010-63925615

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke

  This study tests whether cerebral autoregulation monitoring during thrombectomy can predict futile recanalization and bad outcomes in adults with acute ischemic stroke.

  Recruiting at 4 sites Beijing Shijitan Hospital, Capital Medical University · Beijing and 3 other locations · NCT07747701

• Short-Term outside-in nerve stimulation for acute ischemic stroke

  This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.

  Recruiting Xidian University · Xi'an · NCT07911605

• Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal

  This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.

  Recruiting Phase 3 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Barcelona · NCT07902791

• Safety of adding NRICM301 to standard care for adults with acute ischemic stroke

  This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.

  Recruiting En Chu Kong Hospital · New Taipei City · NCT07900503

• Intracranial Recanalization with LT3001 in Acute Ischemic Stroke

  This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.

  Recruiting Phase 2 Lumosa Therapeutics Co., Ltd. · Taichung · NCT07890298

• Mobilisation After Endovascular Stroke Treatment

  This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

  Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.